Skip to main content
Seqirus Campus View)



New Cell Culture Facility

Project Overview:

Seqirus, the world’s second largest influenza vaccine provider announced plans to construct a new world-class biotech manufacturing facility in Melbourne, Australia to supply influenza vaccines to Australia and the rest of the world, plus Australian antivenoms and Q-Fever vaccine.

Seqirus is a wholly owned subsidiary of CSL Limited, which will invest more than AUD$800 million in capital expenditure to construct the facility. The building is expected to be operational by mid-2026.

The state-of-the-art facility will use innovative cell-based technology to produce influenza vaccines for use in both influenza pandemics and seasonal vaccination programs – and will be the only cell-based influenza vaccine manufacturing facility in the Southern Hemisphere.

The facility will also manufacture Seqirus’ proprietary adjuvant MF59® - a substance added to some vaccines to help improve immune response and to reduce the amount of antigen needed for each vaccine, enabling more doses to be manufactured more rapidly in a pandemic situation.

In addition, the facility will produce unique products important to Australia’s public health needs – including antivenom for Australian snakes, spiders and marine creatures, and the world’s only human vaccine for Q-Fever.

Our Strategic Sourcing Process

At Seqirus, and across the CSL group, we follow a strategic sourcing process to ensure the chosen supplier is aligned with our overall company values and are capable of meeting innovation, cost, quality and time criteria of the project. Our Strategic sourcing process encompasses engagement of cross-functional teams to ensure a fair, transparent and effective process is undertaken.

Key Categories Supported:

Our Procurement team supports a number of different categories to ensure Project Objectives are achieved and to identify supplier capabilities to support operations of the facility when functional. Below is the indicative list of categories that is of interest to the project.

Project phase

Operation phase

Capital goods


Direct Spend

Indirect Spend

Hygienic Vessels

Electrical installation

Raw Materials and Packaging

Building maintenance

Seed & Perfusion Bioreactors

Automation engineering

Buffers, Media and Solutions



Civil construction


Waste Disposal Services

Parts Washers

Piping installation


Cleaning Services

(Clean in Place) CIP Skids

Process & Utility Engineering


IT (Hardware, Software and Digital Technology)

Harvest Filter Skid

Logistic service provider


(Maintenance, Repair & Operations) MRO Services and Supply

Temp Control Unit (TCU) Skids

IT service


Professional Services (Labour Hire and Business Consultancy)

(Microfiltration) MF unit






Warehousing and Logistic service provider

(Water for injection) WFI Stills



Office supplies




Facilities Management

Platform Lifts



Building Automation

Lab Isolators



Trades (Example: Electrical, Plumbing, Fabrication)

Chromatography columns and Skids




Case packing & palletising








Electrical cabinet




Various lab equipment




Registration of interest

If your organisation provides products or services in any of the above listed categories or other relevant categories  and wish to  be considered for any future sourcing events please email your organisation information to

Please note invitation to tenders will be made under the sole discretion of Seqirus.